Laurus Labs, a leading Indian pharmaceutical and biotechnology company, has reported strong financial results for the first quarter of FY26, with consolidated revenues reaching INR 1,570 crore—a 31 percent year-on-year increase.

The company also reported a significant rise in EBITDA to INR 389 crore, up 127 percent, translating to an improved margin of 24.8 percent.

The strong performance was primarily fueled by the continued momentum in the Contract Development and Manufacturing Organisation (CDMO) segment, expanded collaborations in complex APIs, and steady growth in the generics business, according to the company.

Laurus Labs’ CDMO business reported revenues of INR 493 crore during Q1FY26, a growth of 130 percent, driven by multiple mid-to-late stage New Chemical Entity (NCE) project deliveries and ramp-up from new manufacturing assets.

Its generic revenue surged by 12 percent to INR 1,048 crore, supported by strong contributions from the anti-retroviral (ARV) and developed market Finished Dosage Form (FDF) portfolios.

The company’s bio business reported revenues of INR 29 crore during Q1FY26, with growth impacted by customer-specific scale-up and scheduling challenges.

Dr. Satyanarayana Chava, Founder and Chief Executive Officer commented, “We made healthy progress to start the year with increasing contributions from the CDMO business and continued advancement of pipeline projects, supported by Generic FDF. We are moving ahead with strong focus on commercial execution realising the full potential from promising pipeline opportunities, business development and rapidly enhancing scale and technology capabilities.”

He added that construction is underway on several new facilities across CDMO, Generics, and FDF segments. These include a new Gene/ADC facility in Hyderabad and a microbial fermentation plant in Vizag, which is on track for completion by the end of 2026.

“Once complete, these facilities will fortify our ongoing commitment of being a high-quality development and manufacturing partner at scale including advanced therapies. We remain confident in our strategic direction and commitment as the source of sustainable value creation now and well into the future,” Dr. Chava added.

V V Ravi Kumar, Executive Director and CFO, noted that noted that the performance aligns with internal expectations.

 “We will continue to invest fully behind high-value business opportunities to drive near and long-term growth and returns for our shareholders,” he said.

A new finished dosage formulation manufacturing facility is being set up in Hyderabad by Krka Pharma Pvt. Ltd., the joint venture between Laurus Labs and the Slovenian pharmaceutical company Krka. The facility, spread across 19 acres, is aimed at catering to new markets, including India.

The company successfully completed 39 quality audits in Q1 FY26, with no critical findings reported.

Laurus Labs generated INR 5,554 crore in revenue in FY2025.